scholarly journals Investigation of the Relationship between Breast Cancers ‎and HPVs

2018 ◽  
Vol 6 (1) ◽  
pp. 1-9
Author(s):  
Mervat Saeed ◽  
Yasemin ‎Zer ◽  
Zehra Bozdağ
Keyword(s):  
Breast Cancers ◽  
The Relationship

scholarly journals Mitochondrial Fission Regulator 2 (MTFR2) Confers anti-ER Endocrine Therapy Resistance to Breast Cancer Cells by Modulating Mitochondrial Autophagy through Direct Phosphorylation of FUNDC1

2021 ◽  
Author(s):  
Zhanqiang Zhang ◽  
Guanming Lu ◽  
Bo Lin ◽  
Yanghong Li ◽  
Fuju Li ◽  
...  
Keyword(s):  
Endocrine Therapy ◽  
Breast Cancer Cells ◽  
Sequence Similarity ◽  
Mitochondrial Fission ◽  
Therapy Resistance ◽  
Breast Cancers ◽  
Endocrine Therapy Resistance ◽  
Normal Tissues ◽  
The Relationship ◽  
Proliferation And Invasion

Abstract Background: Mitochondrial fission regulator 2 (MTFR2) belongs to the MTFR1/ family with sequence similarity 54 (FAM54) family. Recently, it was reported that MTFR2 promotes the proliferation and invasion of breast cancers (BCs). However, the relationship between MTFR2 and endocrine crine therapy resistance is still unknown.Materials and methods: We collected 36 ER+ BC tissues and adjacent normal tissues and 10 samples from patients who received endocrine therapy. We detected the expression pattern of MTFR2 and the fold change in MTFR2 in cells treated with tamoxifen and letrozole. The autophagy status was also determined.Results: MTFR2 expression was upregulated in ER+ BC tissues and was strongly upregulated in the samples that were treated with endocrine therapy. Knocking out MTFR2 increased BC cell sensitivity to endocrine therapy. In addition, MTFR2 directly bound to FUNDC1 and promoted FUNDC1 phosphorylation, thus inhibiting autophagy.Conclusion: Taken together, our results indicate that increased expression of MTFR2 is associated with endocrine therapy resistance in BC cells. Our findings indicate that MTFR2 could serve as a novel therapeutic target for ER+ BC patients who suffer from endocrine therapy resistance.

Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2532-2532
Author(s):  
Steven M Belknap ◽  
Victoria Godinez-Puig ◽  
Robert E Brannigan ◽  
Simon M Lin ◽  
John Cashy ◽  
...  
Keyword(s):  
Geometric Mean ◽  
Mammary Tissue ◽  
Breast Cancers ◽  
Net Benefit ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Reductase Inhibitors ◽  
Breast Neoplasia ◽  
Urinary Tract Symptoms ◽  
The Relationship

2532 Background: Breast cancers in men (BCM) account for <1% of all breast cancers. Dihydrotestosterone (DHT) inhibits proliferation of normal and neoplastic mammary tissue and constrains the effect of estrogens. Finasteride (F) and dutasteride (D) are 5-α reductase inhibitors (5-αRIs) that reduce systemic and local dihydrotestosterone and cause gynecomastia in 1–3% of men. The package inserts for F and D state, “the relationship between long-term use of (finasteride/dutasteride) and male breast neoplasia is currently unknown.” F and D are marketed for treatment of symptomatic benign-prostatic hyperplasia. F is marketed for treatment of androgenetic alopecia. Methods: To detect disproportionality in the FDA MedWatch dataset, we calculated the empiric Bayes geometric mean (EBGM) for association of BCM with F or D. We also calculated the attributable risk of BCM exposed to F or D among men at an urban academic hospital (Northwestern Memorial Hospital) and at a rural healthcare system (Marshfield Clinic). Results: In the MedWatch dataset, we identified 33 reports of F-associated BCM and 5 reports of D-associated BCM. For F–associated BCM, the EBGM was 58.95 (95% CI 24.47-81.76; p=0.0001). For D-associated BCM, the EBGM was 15.79 (95% CI 4.57-35.49; p=0.0001). The mean age for BCM after 5-αRI exposure was 70±11 years; 11/38 (29%) had gynecomastia. There were 38 cases of BCM associated with 5-αRI in the combined Northwestern and Marshfield cohort (see table below). Conclusions: We found a highly significant association between BCM and 5-αRI exposure in each of 6 separate analyses (3 sources X 2 drugs), with an estimated 1 extra BCM per 564 men exposed to 5-αRIs. We now plan to assess BRCA status and other risk factors. Given that 5-αRIs are marketed for control of lower urinary tract symptoms or for cosmetic purposes, it is not immediately obvious that use of finasteride or dutasteride for their labeled indications would provide any net benefit. [Table: see text]

scholarly journals Characterization of Potential Driver Genes Involved in Human Breast Cancer in Maysan Province, Iraq

2021 ◽  
Author(s):  
Zainab Zamil gataa Allami ◽  
Maytham A Dragh
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Brca1 Gene ◽  
Receptor Expression ◽  
Breast Cancers ◽  
Driver Genes ◽  
Healthy Control ◽  
Hormone Receptor Expression ◽  
The Relationship

Abstract Background: Breast cancer is a heterogeneous disease regarding its morphology, invasive behaviour, metastatic capacity, hormone receptor expression and clinical outcome. There are many risk factors for breast cancer, including genetic factors that account for 25-30% of the incidence; from this percentage, only 15-30% of the heritable component of breast cancer is due to known familiar highly penetrating genes, and the others are sporadic.Methods: This study was the first to include amplified genes as PCR templates to determine the relationship between their polymorphism and breast cancer incidence using RAPD of amplified genes. The study was designed first to evaluate the association of ABCG2, ABCB1 and BRCA1 gene polymorphisms in addition to miRNA-152 and ER-a using the RAPD technique with breast cancer incidence in Maysan Province women and second to use those genes as indicators for breast cancer prediction and diagnosis. The study included 100 patients with breast cancer and 30 healthy control women, and then all samples were amplified by conventional PCR with specific F and R primers for ABCG2, ABCB1, BRCA1, ER-α, and miRNA-152 genes. Then, the best PCR product (20) was chosen as the template for the RAPD technique.Results: The results revealed that all RAPD primers showed polymorphisms with higher values and more specific bands in patient samples. Our study proved the relationship between genetic polymorphisms of breast cancer-related genes and a higher incidence of cancer.Conclusion: The current study recommends employing these results for the future prediction and diagnosis of breast cancers.

scholarly journals From 'to cure' to 'to care' in Oncology Toward shared Evidence based practice

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
F Rubba ◽  
E Paparo ◽  
F Capuano ◽  
E Montella ◽  
I G Continisio ◽  
...  
Keyword(s):  
Social Life ◽  
Life Experience ◽  
Health Workers ◽  
Hospital Staff ◽  
Breast Cancers ◽  
Word Cloud ◽  
Care Givers ◽  
Starting Point ◽  
The Relationship

Abstract Aims Oncological disease need a system of care involving hospital staff and informal caregivers. Care-givers are subjected to stressful factors (burden) with repercussions on psycho-physical balance. The project, carried out together with the ONLUS Travel Companions Association and the Multidisciplinary Oncological Groups (GOM) of Brain and Breast Cancers, intends to offer supportive training experiences for care-givers and health workers, offering emotional and practical preparation for the treatments that they will find themselves providing the cancer relative by helping to improve the quality of care and the relationship between the subjects. The professionals participating in the project (doctors, nurses) take part in a training held by professionals from the Association. The care givers, divided into groups, carry out a CBI test (Caregiver Burden Inventory) and training meetings on medical, psychological and social assistance issues. After 3 months from the end of the course, the care-giver carries out the interview with the psychologist and recompiles the CBI. Furthermore, on 30 selected patients of Breast Cancers, GOM, an emotional evaluation questionnaire of their life experience was administered with respect to the stages of the disease pathway. Results The answers were then analyzed by the word cloud method and summarized in a synthetic map for each question. The most used words to describe the mood during the illness are 'anger, pain, anguish and worry'; while waiting before the visit they are 'long, exhausting, anxious'; towards the doctor 'availability, humanity, kindness, friendliness, professionalism'; with regard to 'excellent, availability' assistance; about social life during the 'unchanged, serene' illness; towards the return home 'joy'. Conclusions The project is a starting point towards a continuous and progressive humanization of the integrated pathways from 'to cure' to 'to care' in oncology. Key messages Patients are positively affected from shared initiatives. Word cloud may resume patients moods and thei main issues concerninthe path.

Relationship between Progesterone Receptor and Productive Fibrosis as an Index of Tumor Differentiation in Breast Cancer

1988 ◽  
Vol 74 (3) ◽  
pp. 287-293 ◽  
Author(s):  
Claudio Giani ◽  
Aldo Pinchera ◽  
Marina Breccia ◽  
Daniela Campani ◽  
Ferdinando De Negri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Steroid Receptors ◽  
Inverse Correlation ◽  
Strongly Correlated ◽  
Breast Cancers ◽  
Regulatory Pathway ◽  
Fibroblastic Cell ◽  
Cell Content ◽  
Degree Of Differentiation ◽  
The Relationship

We studied the relationship between steroid receptors (SR) and various stromal parameters in 100 breast cancers. Each specimen was submitted to SR determination by the dextran-coated charcoal assay and to histologic examination. No relationship was found between the presence of SR and necrosis or fibroblastic cell content. There was an inverse correlation between SR positivity and the extent of lymphocyte infiltration (p < 0.05). ER + PR + status was strongly correlated with marked productive fibrosis (PF) (p < 0.005). When SR were separately assayed, only the presence of PR was correlated with PF (p < 0.005); similar results were obtained for PR levels (p < 0.01). PF was also associated with a higher nuclear grade (p < 0.001). In conclusion, in this study a strong correlation between PR positivity or concentration and extent of PF was demonstrated in breast cancer. Since PR synthesis is an expression of an intact regulatory pathway, our data suggest that stromal production in breast cancer is related to the degree of differentiation of malignant epithelial cells.

scholarly journals Complexities of androgen receptor signalling in breast cancer

2014 ◽  
Vol 21 (4) ◽  
pp. T161-T181 ◽  
Author(s):  
Keely M McNamara ◽  
Nicole L Moore ◽  
Theresa E Hickey ◽  
Hironobu Sasano ◽  
Wayne D Tilley
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Current Knowledge ◽  
Breast Cancer Subtype ◽  
Prognostic Significance ◽  
Breast Cancers ◽  
Cancer Subtypes ◽  
Androgen Action ◽  
Serum Androgens ◽  
The Relationship

While the clinical benefit of androgen-based therapeutics in breast cancer has been known since the 1940s, we have only recently begun to fully understand the mechanisms of androgen action in breast cancer. Androgen signalling pathways can have either beneficial or deleterious effects in breast cancer depending on the breast cancer subtype and intracellular context. This review discusses our current knowledge of androgen signalling in breast cancer, including the relationship between serum androgens and breast cancer risk, the prognostic significance of androgen receptor (AR) expression in different breast cancer subtypes and the downstream molecular pathways mediating androgen action in breast cancer cells. Intracrine androgen metabolism has also been discussed and proposed as a potential mechanism that may explain some of the reported differences regarding dichotomous androgen actions in breast cancers. A better understanding of AR signalling in this disease is critical given the current resurgence in interest in utilising contemporary AR-directed therapies for breast cancer and the need for biomarkers that will accurately predict clinical response.

scholarly journals Trans-fatty acids and cancer: a mini-review

2009 ◽  
Vol 102 (9) ◽  
pp. 1254-1266 ◽  
Author(s):  
Brennan K. Smith ◽  
Lindsay E. Robinson ◽  
Robert Nam ◽  
David W. L. Ma
Keyword(s):  
Fatty Acids ◽  
Cancer Risk ◽  
Genetic Polymorphisms ◽  
Trans Fatty Acids ◽  
Biological Effects ◽  
Mechanisms Of Action ◽  
Experimental Models ◽  
Breast Cancers ◽  
Health And Disease ◽  
The Relationship

The association between trans-fatty acids (TFA) and cancer risk is poorly understood and remains controversial. It is recognised that unique biological effects are associated with specific isoforms within families of fatty acids such as those belonging to the n-3 fatty acids. Furthermore, the interactions between diet and genetic polymorphisms are increasingly recognised for their potential risk-modifying effects on human health and disease. Therefore, the aim of the present review is to evaluate whether specific TFA isomers and genetic polymorphisms differentially modify cancer risk in prostate, colon and breast cancers in animal and human models. Potential mechanisms of action by which TFA may affect cancer development are also reviewed. Overall, across a number of experimental models and human studies, there is insufficient and inconsistent evidence linking specific TFA isomers to cancers of the prostate, colon and breast. A number of methodological limitations and experimental considerations were identified which may explain the inconsistencies observed across these studies. Therefore, further research is warranted to accurately assess the relationship between TFA and cancer risk.

scholarly journals Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline

2021 ◽  
Author(s):  
Hui Kong ◽  
Qianming Bai ◽  
Anqi Li ◽  
Xiaoyan Zhou ◽  
Wentao Yang
Keyword(s):  
Copy Number ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Chromosome 17 ◽  
Clinicopathological Parameters ◽  
Her2 Status ◽  
Breast Cancers ◽  
Luminal A ◽  
Luminal B ◽  
The Relationship

Abstract Background: According to 2018 ASCO/CAP guideline, HER2 FISH-equivocal breast cancers will be categorized as HER2 negative except those with HER2 IHC 3+. However, whether or not HER2 FISH-equivocal breast cancers was a heterogeneous group has not been well illustrated.Methods: 195 HER2 FISH-equivocal breast cancers were collected between 2014 and 2018. The molecular subtype was determined according to 2013 St Gallen consensus, and HER2 status was also redefined following 2018 ASCO/CAP guideline. All cases were classified into 4 groups according to the average HER2 copy number (4.0-4.4, 4.5-4.9, 5.0-5.4, 5.5-5.9 signals/cell). The relationship between HER2 copy number and clinicopathological parameters was analyzed. Results: 183 (93.8%) of 195 FISH-equivocal cases were of luminal subtype, while the other 12 (6.2%) were undetermined. Using 2018 ASCO/CAP guideline, all FISH-equivocal cases were recategorized to HER2 negative. Therefore, 31(15.9%) cases were luminal A-like, 152 (77.9%) were luminal B-like (HER2 negative) and 12 (6.2%) were triple negative. The average HER2 copy number showed positive correlation with chromosome 17 polysomy, but had no significant association with other clinicopathological parameters as well as prognosis. 17 (8.7%) cases were treated with trastuzumab, but showed no difference in prognosis with patients who didn’t receive targeted therapy.Conclusions: In this study, all HER2 FISH-equivocal breast cancers were reclassified to be HER2 negative according to 2018 ASCO/CAP guideline. Most of these patients were luminal B-like (HER2 negative). The average HER2 copy number had no significant association with clinicopathological parameters, as well as prognosis.

Sign in / Sign up

Export Citation Format

Share Document